Leerink Partners analyst Jonathan Chang has reiterated their bullish stance on ZLAB stock, giving a Buy rating on September 3.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jonathan Chang has given his Buy rating due to a combination of factors that highlight Zai Lab’s strategic positioning in the competitive landscape of small cell lung cancer (SCLC) treatment. ZLAB’s ZL-1310, a DLL3 antibody-drug conjugate, has shown a favorable risk-benefit profile in second-line SCLC patients, and it is on track to enter a global registrational study, aiming for accelerated approval by 2027. Despite the absence of new clinical data for ZL-1310 at the 2025 World Conference on Lung Cancer, updates from competitors have reinforced ZLAB’s competitive edge, especially in terms of response durability and tolerability, which are crucial for clinical adoption.
Moreover, Zai Lab’s robust pipeline of commercial and development-stage assets, combined with a management team that possesses significant expertise in the biopharma industry, both in China and internationally, further supports the positive outlook. The company’s capability for fast global execution in the crowded SCLC market is seen as a critical success factor, positioning ZLAB favorably against its peers. Overall, these elements contribute to the reaffirmation of a positive view on Zai Lab, justifying the Buy rating.
According to TipRanks, Chang is an analyst with an average return of -8.6% and a 34.19% success rate. Chang covers the Healthcare sector, focusing on stocks such as Zai Lab, Kura Oncology, and Replimune Group.
In another report released on September 3, Cantor Fitzgerald also maintained a Buy rating on the stock with a $57.00 price target.